



## Clinical trial results:

### Training in intralymphatically injection technique. A realistic learning study

#### Summary

EudraCT number	2014-004031-40
Trial protocol	DK
Global end of trial date	29 November 2020

#### Results information

Result version number	v1 (current)
This version publication date	16 December 2020
First version publication date	16 December 2020

#### Trial information

##### Trial identification

Sponsor protocol code	Version3.22.11.2014
-----------------------	---------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Aarhus University Hospital
Sponsor organisation address	Palle Juul-Jensens Boulevard 99, Aarhus N, Denmark, 8200
Public contact	ILIT Læringsstudie, Department of Respiratory Diseases, Aarhus University Hospital, 0045 7846 2106 , hans.jurgen.hoffmann@ki.au.dk
Scientific contact	ILIT Læringsstudie, Department of Respiratory Diseases, Aarhus University Hospital, 0045 7846 2106 , hans.jurgen.hoffmann@ki.au.dk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	29 November 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 November 2020
Global end of trial reached?	Yes
Global end of trial date	29 November 2020
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

We would like to examine how the new treatment with intralymphatically injections can be learned by doctors with no previous experience in the treatment.

Protection of trial subjects:

Followed Danish regulations

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 November 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Denmark: 175
Worldwide total number of subjects	175
EEA total number of subjects	175

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	175
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Allergic rhinoconjunctivitis.

### Pre-assignment period milestones

Number of subjects started	175
Number of subjects completed	175

### Period 1

Period 1 title	Pre-ILIT grass pollen season
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Intervention
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Alk 225. Phleum Pratense
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intralymphatic use

Dosage and administration details:

1000squ.

Intralymphatic administration

Number of subjects in period 1	Intervention
Started	175
Completed	175

**Period 2**

Period 2 title	Post-ILIT grass pollen season
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	Intervention
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Alk 225. Phleum Pratense
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intralymphatic use

Dosage and administration details:

1000squ.

Intralymphatic administration

<b>Number of subjects in period 2</b>	Intervention
Started	175
Completed	175

**Period 3**

Period 3 title	First injection
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	Intervention
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Alk 225. Phleum Pratense
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intralymphatic use

Dosage and administration details:

1000squ.

Intralymphatic administration

<b>Number of subjects in period 3</b>	Intervention
Started	175
Completed	160
Not completed	15
Lost to follow-up	15

#### **Period 4**

Period 4 title	Second injection
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

#### **Arms**

<b>Arm title</b>	Intervention
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Alk 225. Phleum Pratense
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intralymphatic use

Dosage and administration details:

1000squ.

Intralymphatic administration

<b>Number of subjects in period 4</b>	Intervention
Started	160
Completed	159
Not completed	1
Lost to follow-up	1

**Period 5**

Period 5 title	Third Injection
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	Intervention
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Alk 225. Phleum Pratense
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intralymphatic use

Dosage and administration details:

1000squ.

Intralymphatic administration

<b>Number of subjects in period 5</b>	Intervention
Started	159
Completed	154
Not completed	5
Lost to follow-up	5

## Baseline characteristics

### Reporting groups

Reporting group title	Pre-ILIT grass pollen season
-----------------------	------------------------------

Reporting group description: -

Reporting group values	Pre-ILIT grass pollen season	Total	
Number of subjects	175	175	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	175	175	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	35.2		
standard deviation	± 7.5	-	
Gender categorical Units: Subjects			
Female	63	63	
Male	112	112	

## End points

### End points reporting groups

Reporting group title	Intervention
Reporting group description: -	
Reporting group title	Intervention
Reporting group description: -	
Reporting group title	Intervention
Reporting group description: -	
Reporting group title	Intervention
Reporting group description: -	
Reporting group title	Intervention
Reporting group description: -	

### Primary: Injection score

End point title	Injection score
End point description:	
End point type	Primary
End point timeframe:	
First, second and third injection.	

End point values	Intervention	Intervention	Intervention	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	160	159	154	
Units: 1				
arithmetic mean (standard deviation)	3.3 (± 0.7)	3.2 (± 0.8)	3.3 (± 0.6)	

### Statistical analyses

Statistical analysis title	Injection score
Comparison groups	Intervention v Intervention v Intervention
Number of subjects included in analysis	473
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.12 <sup>[1]</sup>
Method	ANOVA
Parameter estimate	Mean difference (final values)
Point estimate	1



Confidence interval	
level	95 %
sides	2-sided
lower limit	0
upper limit	1
Variability estimate	Standard deviation
Dispersion value	1

Notes:

[1] - Anova p value 0.12.

Parameter estimates not calculated and reported below are fictive numbers.

## Secondary: cSMS

End point title	cSMS
-----------------	------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-ILIT to post-ILIT

End point values	Intervention	Intervention		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	157	157		
Units: 1				
arithmetic mean (confidence interval 95%)				
csms	1.56 (1.53 to 1.77)	1.00 (0.89 to 1.12)		

## Statistical analyses

<b>Statistical analysis title</b>	pre-post cSMS
Comparison groups	Intervention v Intervention
Number of subjects included in analysis	314
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	< 0.0001
Method	t-test, 2-sided
Parameter estimate	Mean difference (final values)
Point estimate	0.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	0.76
Variability estimate	Standard deviation
Dispersion value	0.67



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All study period.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	1
--------------------	---

### Reporting groups

Reporting group title	Intervention
-----------------------	--------------

Reporting group description: -

Serious adverse events	Intervention		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 175 (0.57%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 175 (0.57%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Intervention		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	85 / 175 (48.57%)		
Immune system disorders			
Local reaction			
subjects affected / exposed	85 / 175 (48.57%)		
occurrences (all)	125		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/33099797>